Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses.

ABSTRACT:

Background

The PALISADE study, an international, phase 3 trial of peanut oral immunotherapy (POIT) with AR101, resulted in desensitization in children and adolescents who were highly allergic to peanut. An improved understanding of the immune mechanism induced in response to food allergen immunotherapy would enable more informed and effective therapeutic strategies. Our main purpose was to examine the immunological changes in blood samples from a subset of peanut-allergic individuals undergoing oral desensitization immunotherapy with AR101.

Methods

Blood samples obtained as part of enrollment screening and at multiple time points during PALISADE study were used to assess basophil and CD4+ T-cell reactivity to peanut.

Results

The absence of clinical reactivity to the e

SUBMITTER: Bajzik V 

PROVIDER: S-EPMC9356972 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature